Human Oncology & Pathogenesis Program

The Maurizio Scaltriti Lab

Research

Dr. Maurizio Scaltriti
Maurizio Scaltriti, PhD

My group is focused on understanding why some tumors respond better than others to the inhibition of a given target and how tumor cells cope with pharmacological pressure over time. 

View Lab Overview

Maurizio Scaltriti Lab

Publications

Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Cocco E, Schram AM, Kulick A, Misale S, Won HH, Yaeger R, Razavi P, Ptashkin R, Hechtman JF, Toska E, Cownie J, Somwar R, Shifman S, Mattar M, Selçuklu SD, Samoila A, Guzman S, Tuch BB, Ebata K, de Stanchina E, Nagy RJ, Lanman RB, Houck-Loomis B, Patel JA, Berger MF, Ladanyi M, Hyman DM, Drilon A, Scaltriti M. Nat Med. 2019, Sep;25(9):1422-1427

Tumor specific PI3K inhibition via nanoparticle targeted delivery in head and neck squamous cell carcinoma. Aviram Mizrachi, Yosi Shamay, Janki Shah, Samuel I. Brook, Joanne Soong, Vinagolu K. Rajasekhar, John L. Humm, John H. Healey, Simon N. Powell, José Baselga, Daniel A. Heller*, Adriana Haimovitz-Friedman* and Maurizio Scaltriti*. *Corresponding Authors. Nat Commun, 2017 Feb 13;8:14292

View All Publications

People

Dr. Maurizio Scaltriti

Maurizio Scaltriti, PhD

  • Maurizio Scaltriti studies molecular vulnerabilities and mechanisms of tumor adaptation to targeted therapy.
[email protected]
Email Address

Members

Amaia Arruabarrena Aristorena
Amaia Arruabarrena-Aristorena

Research Fellow

Laura Baldino
Laura Baldino

Research Technician

Yanyan Cai
Yanyan Cai

Research Scholar

Carmen Chan
Carmen Chan

Lab Manager

Emiliano  Cocco
Emiliano Cocco

Research Scholar

Srushti Kittane
Srushti Kittane

Senior Research Technician

Erik Ladewig
Erik Ladewig

Research Fellow

Flavia Michelini
Flavia Michelini

Research Associate

Pedram Razavi, MD, PhD
Pedram Razavi

Assistant Attending, Breast Medicine Service

Mirna Sallaku
Mirna Sallaku

Research Technician

Hong Shao
Hong Shao

Lab Manager

Sophie Shifman
Sophie Shifman

Research Technician

Eneda Toska
Eneda Toska

Senior Research Scientist

Neil Vasan
Neil Vasan

Assistant Attending, Breast Medicine Service

Fan Wu

Research Technician

Guotai  Xu
Guotai Xu

Research Fellow

Lab Alumni
Pau Castel
Pau Castel

Postdoctoral Fellow at HDF Comprehensive Cancer Center, UCSF

Moshe Elkabets
Moshe Elkabets

Assistant Professor, Ben Gurion University Hospital

Natasha Morse
Natasha Morse

PhD Student at NYU

Ana Bosch

Senior Researcher, Lund University, Sweden

Francisco Javier Carmona Sanz
Francisco Javier Carmona Sanz

Senior Editor/Nature Medicine (NPG)

James Cownie
James Cownie

Student, University of Pittsburgh School of Pharmacy

Haley Ellis

Physician, Internal Medicine, Saint Louis, MO

Neel  Jasani
Neel Jasani

PhD Student, Moffit Cancer Center, Tampa

Natalia Martin-Martin
Natalia Martin-Martin

Visiting Investigator

Carles Monterrubio, PhD
Carles Monterrubio

Licensing Associate, MIT

Joanne Soong
Joanne Soong

Senior Research Technician

Zachary Zumsteg
Zachary Zumsteg

Clinical Investigator, Cedars Sinai

Lab Affilations

Lab News & Events

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Maurizio Scaltriti discloses the following relationships and financial interests:

  • American Association for Cancer Research
    Provision of Services (uncompensated)
  • American Society of Clinical Oncology (ASCO)
    Provision of Services (uncompensated)
  • CSRA Inc.
    Provision of Services
  • Daiichi Sankyo
    Provision of Services
  • General Dynamic, Information Technology
    Provision of Services
  • Medendi Medical Travel
    Ownership / Equity Interests
  • Overgroup
    Provision of Services

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures